MedTrace Logo

Attentional Bias Modification Training for People With Chronic Musculoskeletal Pain

NCT02232100 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2021-05-19

No results posted yet for this study

Summary

Chronic musculoskeletal pain is a complex medical condition associated with significant distress, disability, and reduction in quality of life. Research has shown that patients with chronic musculoskeletal pain demonstrate attentional biases towards pain-related information.

The purpose of this study is to determine whether internet-delivered attentional bias modification, which aims to implicitly train attention away from pain-related information, has beneficial effects upon pain and pain-related distress in patients with chronic musculoskeletal pain.

Participants will be randomised to either an attentional training condition, or to a no-training placebo condition. The primary outcome measures are pain intensity and pain interference, and secondary outcome measures include anxiety, depression, pain-related fear and sleep problems.

Data will be analysed and reported separately for participants aged 16 - 24 and 25 - 60. It is hypothesized that participants receiving internet-delivered attentional bias modification will show significantly greater reductions in pain and pain-related distress compared to participants receiving placebo training.

Conditions

Interventions

BEHAVIORAL

Attentional bias modification training (AMG)

Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information

BEHAVIORAL

Attentional bias placebo (ACG)

Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information

Sponsors & Collaborators

  • University of Southampton

    lead OTHER

Principal Investigators

  • Christina Liossi, DPsych · University of Southampton

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-05-01
Completion
2023-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232100 on ClinicalTrials.gov